Gyula Kangiszer, President, RotChrom Technologies North America, developers of the first industrial-scale Centrifugal Partition Chromatography (CPC) technology platform, discusses the partnership with Cyclolab Cyclodextrin Research and Development Laboratory Ltd. (“Cyclolab”) aimed at developing a more efficient and cost-effective process to purify Remdesivir, a direct-acting antiviral agent approved in countries around the world to treat patients with severe cases of COVID-19.Bio
Gyula Kangiszer, President RotaChrom Technologies North America. Gyula is a seasoned strategy and innovation consultant with over 25 years of international experience working for Deloitte, Accenture, Microsoft and EY. He advised leading corporations on a wide range of topics from market strategy through purposeful transformation to operations improvement. Gyula started his career by co-founding and successfully growing a software development company. As the leader of RotaChrom’s North American subsidiary, Gyula is responsible for scaling the operations to stay ahead of the increasing market needs. He also provides strategic advice to customers not only on how to leverage CPC technology, but also how to build their business for long term growth.